TY - JOUR
T1 - Remote intracranial recurrence of IDH mutant gliomas is associated with TP53 mutations and an 8q gain
AU - Nakae, Shunsuke
AU - Kato, Takema
AU - Murayama, Kazuhiro
AU - Sasaki, Hikaru
AU - Abe, Masato
AU - Kumon, Masanobu
AU - Kumai, Tadashi
AU - Yamashiro, Kei
AU - Inamasu, Joji
AU - Hasegawa, Mitsuhiro
AU - Kurahashi, Hiroki
AU - Hirose, Yuichi
N1 - Publisher Copyright:
© Nakae et al.
PY - 2017/10/17
Y1 - 2017/10/17
N2 - Most IDH mutant gliomas harbor either 1p/19q co-deletions or TP53 mutation; 1p/19q co-deleted tumors have significantly better prognoses than tumors harboring TP53 mutations. To investigate the clinical factors that contribute to differences in tumor progression of IDH mutant gliomas, we classified recurrent tumor patterns based on MRI and correlated these patterns with their genomic characterization. Accordingly, in IDH mutant gliomas (N = 66), 1p/19 co-deleted gliomas only recurred locally, whereas TP53 mutant gliomas recurred both locally and in remote intracranial regions. In addition, diffuse tensor imaging suggested that remote intracranial recurrence in the astrocytomas, IDH-mutant with TP53 mutations may occur along major fiber bundles. Remotely recurrent tumors resulted in a higher mortality and significantly harbored an 8q gain; astrocytomas with an 8q gain resulted in significantly shorter overall survival than those without an 8q gain. OncoScan® arrays and next-generation sequencing revealed specific 8q regions (i.e., between 8q22 and 8q24) show a high copy number. In conclusion, only tumors with TP53 mutations showed patterns of remote recurrence in IDH mutant gliomas. Furthermore, an 8q gain was significantly associated with remote intracranial recurrence and can be considered a poor prognostic factor in astrocytomas, IDH-mutant.
AB - Most IDH mutant gliomas harbor either 1p/19q co-deletions or TP53 mutation; 1p/19q co-deleted tumors have significantly better prognoses than tumors harboring TP53 mutations. To investigate the clinical factors that contribute to differences in tumor progression of IDH mutant gliomas, we classified recurrent tumor patterns based on MRI and correlated these patterns with their genomic characterization. Accordingly, in IDH mutant gliomas (N = 66), 1p/19 co-deleted gliomas only recurred locally, whereas TP53 mutant gliomas recurred both locally and in remote intracranial regions. In addition, diffuse tensor imaging suggested that remote intracranial recurrence in the astrocytomas, IDH-mutant with TP53 mutations may occur along major fiber bundles. Remotely recurrent tumors resulted in a higher mortality and significantly harbored an 8q gain; astrocytomas with an 8q gain resulted in significantly shorter overall survival than those without an 8q gain. OncoScan® arrays and next-generation sequencing revealed specific 8q regions (i.e., between 8q22 and 8q24) show a high copy number. In conclusion, only tumors with TP53 mutations showed patterns of remote recurrence in IDH mutant gliomas. Furthermore, an 8q gain was significantly associated with remote intracranial recurrence and can be considered a poor prognostic factor in astrocytomas, IDH-mutant.
KW - 8q gain
KW - IDH mutant gliomas
KW - Intracranial remote recurrence
KW - Radiological classification for recurrence
KW - TP53 mutations
UR - http://www.scopus.com/inward/record.url?scp=85031498436&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85031498436&partnerID=8YFLogxK
U2 - 10.18632/oncotarget.20951
DO - 10.18632/oncotarget.20951
M3 - Article
C2 - 29156679
AN - SCOPUS:85031498436
SN - 1949-2553
VL - 8
SP - 84729
EP - 84742
JO - Oncotarget
JF - Oncotarget
IS - 49
ER -